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Abstract
A better understanding of how the biological functions of the HIV-1 envelope (Env) changes during disease progression
may aid the design of an efficacious anti-HIV-1 vaccine. Although studies from patient had provided some insights on this
issue, the differences in the study cohorts and methodology had make it difficult to reach a consensus of the variations in
the HIV-1 Env functions during disease progression. To this end, an animal model that can be infected under controlled
environment and reflect the disease course of HIV-1 infection in human will be beneficial. Such an animal model was
previously demonstrated by the infection of macaque with SHIV, expressing HIV-1 clade C Env V1-V5 region. By using this
model, we examined the changes in biological functions of Env in the infected animal over the entire disease course. Our
data showed an increase in the neutralization resistance phenotype over time and coincided with the decrease in the net
charges of the V1-V5 region. Infection of PBMC with provirus expressing various Env clones, isolated from the infected
animal over time, showed a surprisingly better replicative fitness for viruses expressing the Env from early time point.
Biotinylation and ELISA data also indicated a decrease of cell-surface-associated Env and virion-associated gp120 content
with disease progression. This decrease did not affect the CD4-binding capability of Env, but were positively correlated with
the decrease of Env fusion ability. Interestingly, some of these changes in biological functions reverted to the pre-AIDS level
during advance AIDS. These data suggested a dynamic relationship between the Env V1-V5 region with the host immune
pressure. The observed changes of biological functions in this setting might reflect and predict those occurring during
natural disease progression in human.
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Introduction
Despite years of efforts, there is no efficacious vaccine against
HIV-1. This impasse is partly due to the highly variable nature of
the HIV-1 envelope gene, which enables viral escape from
immune surveillance [1]. Most of the envelope diversity is within
the V1-V5 region, which encompasses multiple crucial functions,
such as binding to receptor and co-receptors, and can influence
envelope fusion to the cell membrane [2,3,4,5]. Being the major
surface component of HIV-1 envelope, V1-V5 is also constantly
targeted by host humoral responses [6,7]. Given these important
roles, the V1-V5 region is frequently targeted for diverse anti-HIV
strategies. Understanding the changes of HIV-1 envelopes in vivo
may allow prediction of how the envelope will evolve in the
context of host immune suppression, which will be of substantial
importance for future vaccine and drug designs. The first step
towards achieving this goal is to examine how the biological
functions of HIV-1 V1-V5 region evolve during disease progres-
sion. Unfortunately, there is no consensus as to what these changes
might be, due to the difficulties in following individuals from initial
HIV-1 infection throughout disease progression and differences in
methodology.
To address this question, we have previously shown a strikingly
similar molecular evolution of the HIV-1 clade C (HIV-C)
envelope during infection in a Zambian infant (1157i) and an
infant rhesus macaque (RPn-8) infected by SHIV-1157i, a SHIV
expressing the recently transmitted HIV-C envelope of 1157i [8].
This finding validated our macaque model for studying envelope
evolution during disease progression. Importantly, our macaque
model allows studying the longitudinal changes of the biological
functions of the V1-V5 region from an infectious molecular clone
inoculum over the entire disease course. Moreover, significant
mutations were observed within the HIV-C envelope sequences
from different disease stages in the infected macaque RPn-8 [8].
However, whether these envelope mutations translate into
different biological functions remains unanswered. Here, we
addressed this question by characterizing the biological properties
of the V1-V5 region cloned from RPn-8 during disease
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progression. Our hypothesis is that envelopes from various disease
stages have different biological characteristics, which might confer
fitness advantages for the virus.
This study will be of substantial importance since it is the first
reported clade C SHIV (SHIV-C) model that documented
progression to AIDS. Moreover, the recently transmitted Zambian
HIV-C primary isolate we utilized is CCR5 tropic and represents
the dominant clade of HIV-1 infection worldwide [9,10,11,12].
The observed changes in biological functions in this setting should
reflect and predict those occurring during natural disease
progression.
Results
Charged Residues of the HIV-C V1-V5 Region
Charged residues play an important role in protein-protein
interactions by affecting the physiological interactions between
molecules, and might influence HIV-1 envelope-antibody inter-
action, receptor binding as well as disease progression
[13,14,15,16]. Therefore, it was interesting to determine whether
the charges of V1-V5 region varied with disease progression in
monkey RPn-8.
As shown previously, RPn-8 maintained a high viral load
(.16104 copies/ml) throughout the disease course [8] and the
CD4+ T-cell counts gradually declined to ,200 cells/ul from ,28
mpi onwards. The animal was euthanized at 64 mpi due to severe
opportunistic infections [8]. Using ,160 sequences collected
previously across the entire disease course [8], we analyzed the
charged residue distribution within the V1-V5 region. Our
analysis showed a significant increase in the net charge of V1-
V5 region during early infection (6 mpi) compared to the
inoculum (Fig. 1A). However, the net charge decreased substan-
tially by 37 mpi when the CD4+ T-cell counts fell to ,200 cells/
ul. Surprisingly, as RPn-8 had advanced AIDS, the net charge of
the V1-V5 region recovered to pre-AIDS levels.
This pattern of change was mainly caused by the V1-V3 region.
For example, C2 and V3 charges reached the lowest levels by
37 mpi but rebounded later (Fig. 1B). Similar pattern was reported
within the V1V2 of RPn-8 [17]. Other regions, such as V5,
contributed towards the recovery of envelope charges during
advanced AIDS, which was often accompanied by decreases in
regions such as V4 (Fig. 1C). The V1-V5 charges of envelope
clones for subsequent functional analysis are representative to the
envelope population in each time point (Fig. S1).
Neutralization Characteristics
To determine the neutralization characteristics of the V1-V5
region, pseudotype viruses expressing selected V1-V5 Env clones
were tested against naı¨ve, contemporaneous and non-contempo-
raneous plasma from RPn-8. A cell-to-cell fusion assay was first
used to screen out completely non-functional envelope clones. All
functional envelope clones, regardless of their level of cell-to-cell
fusion, were then selected based on their position in the
phylogenetic tree to maximize the representation of various
branches. About five functional envelope clones per time point
were selected for further analysis [8].
We found that neither the naı¨ve nor the contemporaneous
plasma could neutralize any of the envelopes tested, including the
inoculum SHIV-1157i (data not shown). However, non-contem-
poraneous plasma was able to neutralize envelopes from earlier
time points, but this capability tended to decrease with disease
progression (Fig. 2A). This was further confirmed by the
examination of 6 mpi envelopes against plasma samples from all
later time points, where the 64 mpi plasma had the weakest
neutralizing ability (Fig. 2B).
Since plasma from RPn-8 might contain different neutralizing
antibodies, depending on the time points, a reference panel that
consisted of pooled mAbs was used to examine the relative
neutralization sensitivity among the envelopes. Our data show that
envelopes from 6 mpi were mostly sensitive to mAbs (Fig. 2C).
However, the majority of the envelopes displayed increased mAbs
resistance by 37 mpi. Surprisingly, mAbs-sensitive envelopes re-
emerged at 64 mpi.
Replication Kinetics
To determine if envelopes derived from different disease stages
could affect the viral replicative fitness and its relationship with
neutralization sensitivity, proviruses expressing various envelope
clones were generated and their replication kinetics were
examined in PBMC. In addition to the inoculum SHIV-1157i
envelope, nine envelope clones were selected from the 6 (early
infection), 37 (early AIDS) and 64 (advanced AIDS) mpi. Envelope
selection was based on the mAbs neutralization results to
maximize representation of different neutralization characteristics.
As shown in Table 1 (Fig. S2), viruses with 6 month envelopes
(clones #26 and #37) displayed distinctively faster ex-vivo
replication (P= 0.0008) than those with 64 mpi envelopes,
averaging ,7 days to reach half-maximal viral replication using
PBMC from two human donors. In contrast, viruses bearing
envelopes from later time points showed slightly slower ex-vivo
replication compared to the inoculum over time.
Quantity of Envelope on Cell Surfaces and gp120 on
Virions
To further examine the possible reasons for faster ex-vivo
replication of the viruses with early envelopes, we first evaluated
the incorporation of envelopes into virions. By measuring the
gp120 content on virions using ELISA, we showed that the
quantity of surface glycoprotein on virions tended to decline with
disease progression. Viruses expressing the 64 mpi envelopes only
contained an average ,25% (P,0.0001) of gp120 content
compared with those expressing the inoculum SHIV-1157i
envelope (Fig. 3A).
This decreased level of virion-associated gp120 could be caused
by differences in the expression or cleavage of envelope. To
eliminate these possibilities, 293T cell surfaces were labeled with
biotin, immunoprecipitated and the quantity of cell surface-
associated gp160 and 120 was measured by Western blot (Fig. S3).
Our data indicated no significant differences in gp160 expression
levels between all envelopes (Fig. 3B); thereby excluding differ-
ences in gp160 expression on cell surfaces as a plausible cause.
However, we did observe a decrease in cell surface-associated
gp120 levels, which positively correlated with the decline of gp120
content on virions over time (Spearman r= 0.7295, P= 0.0202)
(Fig. 3C). Therefore, the decreased recruitment of surface
glycoprotein onto virions may have been a consequence of having
less cell surface-associated gp120, which subsequently caused an
increase of the cell surface gp160 to 120 ratio over time (Fig. 3D).
This was further supported by the negative correlation (Spearman
r= -0.8909, P= 0.0011) between the cell surface gp160 to 120
ratio and gp120 quantity on virions (Fig. 3D). Together, our data
strongly suggest a deficiency in cleavage or trafficking of cleaved
envelope to cell surfaces with disease progression.
Clade C Env Changes during Disease Progression
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Figure 1. Distribution of charged residues within the V1-V5 envelope region. Each symbol represents one V1-V5 sequence. SHIV-1157i is
the inoculum envelope, followed by envelopes from 6, 20, 37, 50 and 64 months pi. (A) Net charge of the V1-V5 region. (B) Charge distribution within
the C2 and V3 region. (C) Charge distribution within V4 and V5 region.
doi:10.1371/journal.pone.0066973.g001
Clade C Env Changes during Disease Progression
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Envelope Binding to CD4
Another possible factor that can influence ex-vivo replication is
divergence in the envelope-CD4 binding capacity. To this end,
our in-vitro CD4 binding assay showed that the CD4 binding
proficiency of envelope improved with disease progression. At
37 mpi, the envelopes had significantly enhanced binding to CD4
compared with the inoculum (Fig. 4). Surprisingly, this enhanced
CD4 binding capability was not maintained and reverted to pre-
AIDS levels during advanced AIDS.
Envelope Fusion to Target Cell
Fusion of viral envelope to target cell is a critical rate-limiting
step that could affect ex-vivo replication. A FRET-based virus-to-
cell fusion assay was used to examine the fusion efficiency of
envelopes from various time points. Our result showed that viruses
expressing the 6 mpi envelopes, except #5, had significantly
enhanced fusion abilities compared with the inoculum
(P=,0.0001) (Fig. 5A). Envelopes isolated from 37 mpi displayed
a diverse fusion capability, with 37 month #1 having fusion ability
close to the 6 mpi and the rest having lower fusion ability
compared to the inoculum (Fig. 5A). Additionally, this weak fusion
phenotype dominated among envelopes isolates from advanced
AIDS (Fig. 5A). This suggests that envelope fusion ability increased
during early infection, but gradually declined with disease
progression.
Discussion
This study showed that the V1-V5 regions of HIV-C envelope
underwent significant changes in their biological characteristics
throughout disease progression. Envelopes from early infection
were more positively charged, neutralization sensitive and had
faster ex-vivo replication and enhanced fusion capability. During
early AIDS, the envelopes became more negatively charged with
diminished functional capabilities ranging from ex-vivo replication
Figure 2. Envelope neutralization characteristics. (A) Pseudo-
typed viruses with envelopes from 6 months pi were tested against
non-contemporaneous plasma from 20 months pi, 20 months pi were
tested against non-contemporaneous plasma from 37 months pi, 37
months pi envelope clones against 50 months pi plasma and 50 months
pi envelope clones against 64 months pi plasma. Each symbol
represents a pseudotyped virus encoding an individual envelope clone
from that particular time point. (B) Pseudotyped viruses with envelopes
from 6 month pi were tested against plasma of 37, 50 and 64 months pi.
(C) Pseudotyped viruses with envelopes from various time points were
tested against pooled mAbs. Envelopes from the infectious molecular
clone inoculum (SHIV-1157i), murine leukemia virus (MLV) and NL4-3
served as controls. Each symbol represents a pseudotyped virus
encoding an individual envelope clone from that particular time point.
doi:10.1371/journal.pone.0066973.g002
Table 1. Ex-vivo replication of infectious viruses, expressing
varies V1-V5 region, in PBMC.
Half-time of maximal viral replication (days)
Envelopes Donor 1 Donor 2
SHIV-1157i 9.739 8.951
6 month #5 10.032 10.798
* 6 month #26 7.099 7.083
* 6 month #37 6.510 6.315
37 month #1 10.555 10.813
37 month #11 8.998 9.797
37 month #S1 11.207 12.258
64 month #13 11.922 15.105
64 month #30 9.880 11.130
64 month #46 10.414 12.496
*Denote statistical significances (P = 0.0008) in comparison with the 64 month
envelopes.
doi:10.1371/journal.pone.0066973.t001
Clade C Env Changes during Disease Progression
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Figure 3. Quantity of envelope on cell surfaces and gp120 on virions. (A) Quantities of gp120 on virions expressing selected V1-V5 region
from each time point. (B) Relative levels of 293T cell surface-associated gp160. (C) Correlation between the levels of virion-associated gp120 (black
bars) and 293T cell surface-associated gp120 (red dots). (D) Correlation between the levels of virion-associated gp120 (black bars) and the ratio of
293T cell surface-associated gp160–120 (red dots).
doi:10.1371/journal.pone.0066973.g003
Clade C Env Changes during Disease Progression
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to incorporation into virions. However, these envelopes did have
significantly improved CD4 binding ability and were more
neutralization resistant. Interestingly, the envelopes showed
multiple reversions in their biological properties during advanced
AIDS. For example, their charges, neutralization sensitivity and
CD4 binding efficiency had all reverted to pre-AIDS levels.
However, other functions remained relatively poor.
Our results are surprising given the current belief that viral
fitness increases over time due to envelope evolution [18,19]. It is
possible that the previous studies were unable to capture the early
infection in adult HIV-1 patients and used PBMC co-cultured
viral quasi-species for biological analysis. Our study represents
envelope isolates throughout the disease spectrum, focusing on V1-
V5 region changes. At the early infection of 6 mpi, monkey infant
RPn-8 had an unambiguously higher CD4+ T-cell counts of
.2000 cells/ul, which was age-appropriate, and high viral loads
compared to reports of other investigators, reflecting acute
infection [8]. Moreover, having an isogenic backbone allowed us
to focus on the V1-V5 region without the influences from other
viral genes. Our use of PBMC for ex-vivo replication also better
represents the in-vivo scenario than the cell lines used in previous
study [2]. Alternatively, the different maturation state of the
immune system between adults and infants during the initial
infection might affect the evolutionary pressure placed on the
virus.
Our study suggests that during early infection, the host immune
system is intact and exerts selective pressures on the viruses, as the
relatively early plasma can easily neutralized the early envelopes.
To counter this host constraint, the envelope evolved compensa-
tory mutations that resulted in more efficient fusion and faster
replication kinetics, increasing the likelihood for the virus to infect
new cells before being neutralized by the immune system. This
possibility that early envelopes might have better fitness was
mathematically predicted previously and observed recently in
HIV-1 patients [20,21]. Although the exact mechanism of this
outcome is still controversial, the ‘‘Red Queen’’ hypothesis was
proposed as a possible explanation, where beneficiary mutations
evolved in responses to immune selection resulting in increased
fitness of the early envelopes [21,22,23].
During early AIDS, some immune pressure persisted as evident
by the presence of neutralization-resistant envelopes and was also
reported by others [13,24]. Importantly, the appearance of
neutralization-resistant phenotypes coincided with a significant
drop in the net charges of V1-V5 region. This strongly suggests
that variations in net charges could be an escape mechanism
employed by the envelope to evade humoral responses beside its
glycan shield [7]. The high CD4 binding ability of the envelopes at
this stage could be another compensatory mutation for more
efficient infection in an environment with limited availability of
CD4+ T cells.
Another unexpected finding from our study is that viral fitness
linked to the V1-V5 region, as defined by the ex-vivo replication of
isogenic viruses differing only in their V1-V5 regions, did not
improve despite reversion of several envelope properties during
advanced AIDS. Importantly, the gp120 content on cell surface
and on virion gradually decreased as disease progressed. Addi-
tionally, with the exception of the CD4 binding site mutant 6
month #5, decreased levels of gp120 on virion correlated with the
decline in fusion ability from early infection to advanced AIDS
(Spearman r= 0.7667, P = 0.0214) (Fig. 5B). These changes could
be evasive responses toward immune surveillance and ultimately
affected the neutralization sensitivity as suggested earlier [25]. The
severe depletion of CD4+ T cells and absence of immune selection
might facilitate the accumulation of deleterious mutations, possibly
Figure 4. Envelope binding to CD4 and virus fusion with target cells. Purified viruses, expressing selected V1-V5 regions from each time
point, were tested with in-vitro CD4 binding assay to determine their half maximum binding to CD4-IgG2. Each symbol for individual envelope clones
represents an independent experiment. ‘‘*’’ represent statistical significant compare to the inoculum, SHIV-1157i. The value of 6 month #5 may not
reflect the actual data since it falls beyond the maximum range of our assay.
doi:10.1371/journal.pone.0066973.g004
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yielding envelopes with lower fitness reminiscent to the effect of
‘‘Muller’s ratchet’’ hypothesis [26,27,28,29]. The lack of immune
surveillance during the advanced AIDS might allow accumulation
of viruses with lower fitness envelopes, resulting in the increase of
plasma viral load.
Our study is based on retrospectively collected specimens from
an animal that developed AIDS and no other specimens or
animals were available for further analysis, the changes we
observed could be only confined to this animal. However, the
lessons we learned from this study cannot be underestimated, as
this is the first study of a SHIV-C-infected macaque that
progressed to AIDS. To our knowledge, this is also the first study
that demonstrated a decrease of gp120 content on virion with
disease progression. Although gp120 shedding might reduce the
gp120 content on virion, it was unlikely in our case as suggested by
other investigators [30]. By focusing on the V1-V5 region, we
cannot eliminate the role of other viral genes or envelope regions,
such as the signal peptide and gp41, in the overall viral fitness [31].
However, our data strongly suggest that V1-V5 region plays a
major role in disease progression [32,33]. Also, the presence of
mixed population at any time points due to reactivation of latent
viral reservoirs cannot be excluded.
Figure 5. Envelope fusion with target cells was measured using FRET-based virus-to-cell fusion assay. (A) An example for the detection
of fluoresce emission shift from green (fusion negative) to blue (fusion positive) by flow cytometry was shown above the graph. The graph shows
percentage of fusion-positive cells for individual envelope clones from each time point relative to the inoculum, SHIV-1157i. All differences were
statistically significant compared to the inoculum. (B) Correlation between the levels of virion-associated gp120 (black bars) and fusion-positive cells
(red dots). The 6 month #5 is excluded from this correlation analysis since it is a CD4 binding site mutant.
doi:10.1371/journal.pone.0066973.g005
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Our findings underscore the dynamic interaction between host
immune selection and HIV-1 envelope evolution. Our emphasis
on the V1-V5 region had shed light on the evolution of its unique
properties during disease progression. Moreover, variations in the
envelope CD4 binding and fusion ability might suggest some
corresponding structural changes with disease progression, which
could have substantial implications for the development of
vaccines and small molecule inhibitors.
Materials and Methods
Animal and Animal Care
An infant Indian rhesus macaque (RPn-8) was intravenously
inoculated with SHIV-1157i, a SHIV-C expressing the envelope
of a recently transmitted Zambian pediatric HIV-C. The infected
animal was monitored from inoculation until euthanasia due to
AIDS (,5 years). Details of animal care and procedures were
described [8,34]. The animal was housed and cared for according
to the National Institutes of Health Guidelines on the Care and
Use of Laboratory Animals at the Yerkes National Primate
Research Center (YNPRC), which is fully accredited by the
Association for Assessment and Accreditation of Laboratory
Animal Care International. The animal is kept in two level
Allentown stainless steel cage racks commensurate with the size
and needs of the animal. The animal cage pans are cleaned daily
with weekly cage changes. The animal quarter is maintained with
controlled air humidity and quality, as well as a 12 hour on/off
schedule for access to light. Commercial monkey chow is fed to the
animal daily with supplemented fresh fruit or vegetable and
drinking water is available at all times. Environmental enrichment
is provided daily in the form of devices that provide foraging
opportunities and toys such as kongs. The animal is monitored at
least twice a day with medical care provided by Yerkes staff
veterinarians. All sample collections were performed under
ketamine/Telazol anesthesia to alleviate any pain or stress and
recovery of the animal was closely monitored. Euthanasia of the
animal is performed in accordance with recommendations of the
American Veterinary Medical Association using an overdose of
pentobarbital. Humane endpoints have been defined by the
Emory IACUC and include perimeters such as weight loss
exceeding 25% and untreatable disease that cannot be alleviated
therapeutically. All animal procedures were approved by the
Animal Care and Use Committees of the YNPRC and the Dana-
Farber Cancer Institute.
Construction and Preparation of Viruses
The SHIV-1157i inoculum used for the infection of macaque
was prepared as described [34,35]. Genomic DNA was extracted
from PBMC samples of RPn-8 collected at 6, 20, 37, 50 and 64
months post-infection (mpi). The V1-V5 region was amplified
from genomic DNA and cloned into the envelope expression
(pSRH NLA/S/Av) and provirus (pNL4-3 A/S/Av) plasmids as
described [8,36,37]. Thus, both types of plasmids bear a chimeric
HIV-1 NL4-3 envelope with its V1-V5 region derived from RPn-
8. Importantly, this mirrors the chimeric nature of the inoculum,
SHIV-1157i, which consists of the HIV-1 HXBc2 and clade C
envelope [35]. Infectious virus was generated by transfection of
293T cells with the proviral plasmids, supernatant was collected
and filtered at 48 hrs post-transfection (pt). For purified virus, the
filtered supernatant was concentrated by ultracentrifuge and the
resulting virus pellet was re-suspended in their respective assay
medium.
Envelope Charge Analysis
V1-V5 region sequences were obtained from the previous study
[8]. Charged residues of the envelope were computed using
AminoTrackTM [38]. The value of +1 was assigned to positively
charged arginine and lysine. The value of -1 was assigned to
negatively charged aspartic acid and glutamic acid. GraphPad
Prism 5 (GraphPad Software) was used for statistical analysis.
Neutralization Assay
Pseudotyped viruses were generated by co-transfection of COS-
1 cells with the envelope expression and backbone pNL4-3-deltaE-
GFP plasmids, supernatants were collected and filtered at 48 hrs
pt. Pseudotyped virus encoding NL4-3 and SV-A-MLV envelopes
served as controls. Next, 16104 TZM-bl cells/well were seeded
into 96-well plates 24 hrs before the assay. Heat-inactivated
plasma samples of RPn-8 were 3-fold serially diluted starting from
1:20. Pooled monoclonal antibodies (mAbs) were prepared by
mixing equal concentrations of the broadly neutralizing anti-HIV-
1 mAbs 2F5, 4E10, 2G12 and b12, followed by 3-fold serially
dilutions starting from 80 ug/ml (total concentration of all mAbs
in the mixture). An inoculum of 300 50% tissue culture infectious
doses (TCID50)/ml of pseudotyped viruses was supplemented with
80 ug/ml DEAE-dextran and mixed with an equal volume of
either the serially diluted heat-inactivated plasma or pooled mAbs.
The mixture was incubated for 1 hr at 37uC before addition to
TZM-bl cells in triplicates. After 48 hrs incubation at 37uC, the
cells were washed, lysed with Luciferase Assay System reagents
(Promega) and its luciferase activity measured by luminometer.
The 50% inhibitory concentration (IC50) in ug/ml and reciprocal
IC50 were calculated using GraphPad Prism 5.
Viral Replication Kinetics
Infectious viruses bearing the V1-V5 region of RPn-8 were used
to infect PBMC from HIV-1-seronegative donors. PHA-stimulated
PBMC (3.56105 cells) were infected at a multiplicity of infection
(MOI) of 0.05 overnight at 37uC in duplicates. The next day, the
infected cells were washed and resuspended in RPMI growth
medium containing human interleukin-2 (hIL-2) (Roche Applied
Science). Cell-free supernatants were collected every 3 days. The
level of reverse transcriptase (RT) activity in 10 ml of collected
supernatants was determined in triplicates by the standard RT
activity assay and expressed in counts-per-minute (CPM) [39]. The
experiment was repeated using a different HIV-1-seronegative
donor PBMC.
Quantification of Virus-associated gp120
The amount of virus-associated HIV-1 surface glycoprotein was
measured using ELISA as described [40]. Briefly, 96-well plates
were coated overnight with anti-gp120 antibody D7324 (Aalto Bio
Reagents Ltd), followed by washing with Tris-buffered saline
(TBS) and blocked with nonfat-milk solution. Purified virus
(100 ng/ml p24 equivalents) was lysed and added to the plates
in triplicates for 5 hrs incubation at 37uC. Unbound proteins were
removed by extensive washes. For detecting captured gp120, mAb
T43 (NIH) was added at room temperature. Importantly, the mAb
T43 epitope lies within the envelope C1 region, which is identical
among all our samples. The plates were washed and captured
gp120 was detected by addition of goat anti-mouse horseradish
peroxidase (Jackson ImmunoResearch Laboratories) with 1-Step
Ultra-TMB-ELISA substrate (Pierce). Gp120 quantity was mea-
sured by microplate reader and calculated by comparison with a
standard curve generated using serial dilutions of purified HIV-C
1157ip gp120 with a known concentration.
Clade C Env Changes during Disease Progression
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Quantification of Cell Surface-associated Envelope
Labeling of cell-surface proteins with biotin was described [41].
Briefly, 293T cells transfected with proviral plasmids were
harvested at 48 hrs pt, washed and incubated with 1 mg/ml of
EZ-Link Sulfo-NHS-LC-biotin (Thermo Scientific) for 30 min on
ice, followed by extensive washes and addition of lysis buffer
containing proteinase inhibitor cocktail. Cellular debris was
removed and the total protein concentration in the cleared lysates
was measured using a Pierce BCA protein assay kit (Pierce). Equal
amounts of total protein were used for HIV-1 envelope
immunoprecipitation with HIV-IG (NIH) overnight at 4uC. The
immune complexes were pulled down with Protein A/G Ultra-
Link Resin (Thermo Scientific), washed and boiled in 2X SDS-
PAGE sample buffers. Resin-free supernatant containing the
immunoprecipitated proteins was resolved by Western blot.
Biotinylated proteins were detected using streptavidin-conjugat-
ed-680 secondary antibody (Li-Cor Biosciences) and visualized by
Odyssey infrared imager (Li-Cor Biosciences). Respective band
intensity of the cell surface-associated HIV-1 envelope was
analyzed using Odyssey application software version 3.0.
In-vitro CD4 Binding
Envelope CD4 binding capability was determined by ELISA.
Briefly, purified virus (10 ng/ml gp120 equivalents) was lysed and
captured with D7324-coated plates in triplicates. Serial dilutions of
CD4-IgG2 with known concentrations were added and incubated
overnight at room temperature. Unbound CD4-IgG2 was
removed by extensive washes. CD4-IgG2 bound to gp120 was
detected by addition of goat-anti-human horseradish peroxidase
(Santa Cruz Biotechnology) with 1-Step Ultra-TMB-ELISA
substrate (Pierce) and measured by microplate reader. Half-
maximal binding concentration (ng/ml) of CD4-IgG2 was
calculated for each sample.
FRET-based Virus-to-cell Fusion
The fluorescent resonance energy transfer (FRET)-based virus-
to-cell fusion assay was described [42,43]. Briefly, infectious viruses
bearing the V1-V5 region of RPn-8 and the b-lactamase HIV-
1 Vpr fusion protein (BlaM-Vpr) were generated by co-transfec-
tion of 293T cells with the provirus, pAdVantage (Promega) and
pMM310 plasmids (NIH). Supernatants were collected at 48 hrs
pt and purified as described earlier. The p24 concentration of
purified viruses were measured with HIV-1 p24 ELISA (Perkin-
Elmer). Then, 2.56105 SupT1/CCR5 cells [44] were incubated
with 50 ng of p24 of the purified viruses for 2 hrs at 37uC in 96-
well plates in triplicates. The infected cells were washed and
resuspended in the CCF2-AM loading solution from GeneBLAzer
Detection Kits (Invitrogen) for 1 hr at room temperature in the
dark. The CCF2-AM-loaded cells were washed, resuspended in
10% FBS medium with probenecid and incubated overnight at
room temperature in the dark. The next day, CCF2-AM-loaded
cells were washed and fixed for flow cytometry. Once the BlaM-
Vpr viruses fused with the target cell, b-lactamase will cleave the
CCF2-AM dye and alter its fluorescence emission spectrum from
520 nm (green) to 447 nm (blue). This change in fluorescence
emission was detected by Cytek DxP10 (Cytek Development) and
analyzed using FlowJo software v7.9 (TreeStar). GraphPad Prism
5 was used for statistical analysis.
Supporting Information
Figure S1 The V1-V5 charges of envelope clones select-
ed for various functional analysis. Triangle (m) symbol
represent envelope clones used for neutralization assay. Envelope
clones used for other functional analysis are shown in red.
(PDF)
Figure S2 Ex-vivo replication of infectious viruses,
expressing the V1-V5 region from the inoculum clone,
SHIV-1157i, and varies time points. (A) Replication kinetic
in PBMC from donor JW. (B) Replication kinetic in PBMC from
donor JC.
(PDF)
Figure S3 Example of a western blot for the biotinylated
and immunoprecipitated cell surface-associated HIV-1
envelope after transfection of 293T cells with the
proviral constructs encoding the V1-V5 regions from
the inoculum SHIV-1157i and other time points. The data
is an example of the several experiments conducted.
(PDF)
Acknowledgments
The following reagent was obtained through the NIH AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH: pMM310
from Dr. Michael Miller [42,45]; pNL4-3-deltaE-EGFP from Drs. Haili
Zhang, Yan Zhou, and Robert Siliciano [46]; TZM-bl cells from Drs. John
C. Kappes, Xiaoyun Wu and Tranzyme Inc [47]; SV-A-MLV-env from
Drs. Nathaniel Landau and Dan Littman [48]; Broadly neutralizing HIV-
1 mAbs [49,50,51,52]; HIV-IG from NABI and NHLBI. We would like to
thank Dr. James A. Hoxie for SupT1/CCR5 cells [44], Drs. Earl Patricia
and Bernie Moss for mAb T43. We thank Dr Marielle Cavrois for her
advice with the FRET-based virus to cell fusion assay and Dr Francois
Villinger for his assistance in manuscript preparation.
Author Contributions
Conceived and designed the experiments: RMR CW. Performed the
experiments: FYT LA. Analyzed the data: FYT LA. Contributed reagents/
materials/analysis tools: SLH RMR. Wrote the paper: FYT.
References
1. Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, et al. (2008)
Deciphering human immunodeficiency virus type 1 transmission and early
envelope diversification by single-genome amplification and sequencing. J Virol
82: 3952–3970.
2. Etemad B, Fellows A, Kwambana B, Kamat A, Feng Y, et al. (2009) Human
immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic
phase of infection use CCR5 and fuse more efficiently than those from early after
infection. J Virol 83: 9694–9708.
3. Kozak SL, Platt EJ, Madani N, Ferro FE, Jr., Peden K, et al. (1997) CD4,
CXCR-4, and CCR-5 dependencies for infections by primary patient and
laboratory-adapted isolates of human immunodeficiency virus type 1. J Virol 71:
873–882.
4. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, et al. (1996) CD4-
dependent, antibody-sensitive interactions between HIV-1 and its co-receptor
CCR-5. Nature 384: 184–187.
5. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, et al. (1996) CD4-induced
interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor
CCR-5. Nature 384: 179–183.
6. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus
type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over
the course of infection, and these modifications affect antibody neutralization
sensitivity. J Virol 80: 9586–9598.
7. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody
neutralization and escape by HIV-1. Nature 422: 307–312.
8. Tso FY, Hoffmann FG, Tully DC, Lemey P, Rasmussen RA, et al. (2009) A
comparative study of HIV-1 clade C env evolution in a Zambian infant with an
infected rhesus macaque during disease progression. AIDS 23: 1817–1828.
9. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. (1996) The beta-
chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1
isolates. Cell 85: 1135–1148.
Clade C Env Changes during Disease Progression
PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6 | e66973
10. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, et al. (1996) Identification of
a major co-receptor for primary isolates of HIV-1. Nature 381: 661–666.
11. Pope M, Haase AT (2003) Transmission, acute HIV-1 infection and the quest
for strategies to prevent infection. Nat Med 9: 847–852.
12. Hemelaar J, Gouws E, Ghys PD, Osmanov S (2011) Global trends in molecular
epidemiology of HIV-1 during 2000–2007. AIDS 25: 679–689.
13. Borggren M, Repits J, Sterjovski J, Uchtenhagen H, Churchill MJ, et al. (2011)
Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5
HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One 6:
e20135.
14. Morikis D, Rizos AK, Spandidos DA, Krambovitis E (2007) Electrostatic
modeling of peptides derived from the V3-loop of HIV-1 gp120: implications of
the interaction with chemokine receptor CCR5. Int J Mol Med 19: 343–351.
15. Seclen E, Soriano V, del Mar Gonzalez M, Gonzalez-Lahoz J, Poveda E (2011)
Short communication: severe immune suppression in patients infected with R5-
tropic HIV-1 strains is associated with increased gp120 net charge at variable
regions. AIDS Res Hum Retroviruses 27: 965–967.
16. Repits J, Sterjovski J, Badia-Martinez D, Mild M, Gray L, et al. (2008) Primary
HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in
parallel with increased gp120 net charge. Virology 379: 125–134.
17. Tso FY, Tully DC, Gonzalez S, Quince C, Ho O, et al. (2012) Dynamics of
envelope evolution in clade C SHIV-infected pig-tailed macaques during disease
progression analyzed by ultra-deep pyrosequencing. PLoS One 7: e32827.
18. Repits J, Oberg M, Esbjornsson J, Medstrand P, Karlsson A, et al. (2005)
Selection of human immunodeficiency virus type 1 R5 variants with augmented
replicative capacity and reduced sensitivity to entry inhibitors during severe
immunodeficiency. J Gen Virol 86: 2859–2869.
19. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, et al. (2005)
Changes in human immunodeficiency virus type 1 fitness and genetic diversity
during disease progression. J Virol 79: 9006–9018.
20. Wodarz D, Levy DN (2007) Human immunodeficiency virus evolution towards
reduced replicative fitness in vivo and the development of AIDS. Proc Biol Sci
274: 2481–2490.
21. Arnott A, Jardine D, Wilson K, Gorry PR, Merlin K, et al. (2010) High viral
fitness during acute HIV-1 infection. PLoS One 5.
22. Van Valen L (1974) Molecular evolution as predicted by natural selection. J Mol
Evol 3: 89–101.
23. Clarke DK, Duarte EA, Elena SF, Moya A, Domingo E, et al. (1994) The red
queen reigns in the kingdom of RNA viruses. Proc Natl Acad Sci U S A 91:
4821–4824.
24. Bunnik EM, van Gils MJ, Lobbrecht MS, Pisas L, van Nuenen AC, et al. (2009)
Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and
4E10 of primary subtype B human immunodeficiency virus type 1 variants in the
natural course of infection. Virology 390: 348–355.
25. Blay WM, Kasprzyk T, Misher L, Richardson BA, Haigwood NL (2007)
Mutations in envelope gp120 can impact proteolytic processing of the gp160
precursor and thereby affect neutralization sensitivity of human immunodefi-
ciency virus type 1 pseudoviruses. J Virol 81: 13037–13049.
26. Chao L (1990) Fitness of RNA virus decreased by Muller’s ratchet. Nature 348:
454–455.
27. Duarte E, Clarke D, Moya A, Domingo E, Holland J (1992) Rapid fitness losses
in mammalian RNA virus clones due to Muller’s ratchet. Proc Natl Acad
Sci U S A 89: 6015–6019.
28. Muller HJ (1964) The Relation of Recombination to Mutational Advance.
Mutat Res 106: 2–9.
29. Yuste E, Sanchez-Palomino S, Casado C, Domingo E, Lopez-Galindez C (1999)
Drastic fitness loss in human immunodeficiency virus type 1 upon serial
bottleneck events. J Virol 73: 2745–2751.
30. Chertova E, Bess JW Jr, Crise BJ, Sowder IR, Schaden TM, et al. (2002)
Envelope glycoprotein incorporation, not shedding of surface envelope
glycoprotein (gp120/SU), Is the primary determinant of SU content of purified
human immunodeficiency virus type 1 and simian immunodeficiency virus.
J Virol 76: 5315–5325.
31. Asmal M, Hellmann I, Liu W, Keele BF, Perelson AS, et al. (2011) A signature
in HIV-1 envelope leader peptide associated with transition from acute to
chronic infection impacts envelope processing and infectivity. PLoS One 6:
e23673.
32. Kwa D, Vingerhoed J, Boeser B, Schuitemaker H (2003) Increased in vitro
cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency
virus type 1 primary isolates correlates with a progressive clinical course of
infection. J Infect Dis 187: 1397–1403.
33. Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, et al. (1998)
Correlation between humoral responses to human immunodeficiency virus type
1 envelope and disease progression in early-stage infection. J Infect Dis 178:
1306–1316.
34. Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, et al. (2008) SHIV-
1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause
AIDS in rhesus monkeys. Retrovirology 5: 94.
35. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, et al. (2006)
Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent,
mucosally transmissible R5 simian-human immunodeficiency virus encoding
HIV clade C Env. J Virol 80: 8729–8738.
36. Zhang H, Rola M, West JT, Tully DC, Kubis P, et al. (2010) Functional
properties of the HIV-1 subtype C envelope glycoprotein associated with
mother-to-child transmission. Virology 400: 164–174.
37. Zhang H, Tully DC, Zhang T, Moriyama H, Thompson J, et al. (2010)
Molecular determinants of HIV-1 subtype C coreceptor transition from R5 to
R5X4. Virology 407: 68–79.
38. Mahalanabis M, Blue J, Haigwood NL (2006) AminoTrackTM : Automating the
Entry and Analysis of Mutations in Multiple Protein Sequences Using a
Spreadsheet Format. In: Arabnia HR, editor. Las Vegas, NV. CSREA Press.
549–555.
39. Hoffman AD, Banapour B, Levy JA (1985) Characterization of the AIDS-
associated retrovirus reverse transcriptase and optimal conditions for its
detection in virions. Virology 147: 326–335.
40. Binley JM, Klasse PJ, Cao Y, Jones I, Markowitz M, et al. (1997) Differential
regulation of the antibody responses to Gag and Env proteins of human
immunodeficiency virus type 1. J Virol 71: 2799–2809.
41. Abrahamyan LG, Markosyan RM, Moore JP, Cohen FS, Melikyan GB (2003)
Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond
engages coreceptors but requires bond reduction after engagement to induce
fusion. J Virol 77: 5829–5836.
42. Cavrois M, De Noronha C, Greene WC (2002) A sensitive and specific enzyme-
based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat
Biotechnol 20: 1151–1154.
43. Cavrois M, Neidleman J, Bigos M, Greene WC (2004) Fluorescence resonance
energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol 263: 333–
344.
44. Means RE, Matthews T, Hoxie JA, Malim MH, Kodama T, et al. (2001) Ability
of the V3 loop of simian immunodeficiency virus to serve as a target for
antibody-mediated neutralization: correlation of neutralization sensitivity,
growth in macrophages, and decreased dependence on CD4. J Virol 75:
3903–3915.
45. Tobiume M, Lineberger JE, Lundquist CA, Miller MD, Aiken C (2003) Nef
does not affect the efficiency of human immunodeficiency virus type 1 fusion
with target cells. J Virol 77: 10645–10650.
46. Zhang H, Zhou Y, Alcock C, Kiefer T, Monie D, et al. (2004) Novel single-cell-
level phenotypic assay for residual drug susceptibility and reduced replication
capacity of drug-resistant human immunodeficiency virus type 1. J Virol 78:
1718–1729.
47. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D (1998) Effects of
CCR5 and CD4 cell surface concentrations on infections by macrophagetropic
isolates of human immunodeficiency virus type 1. J Virol 72: 2855–2864.
48. Landau NR, Page KA, Littman DR (1991) Pseudotyping with human T-cell
leukemia virus type I broadens the human immunodeficiency virus host range.
J Virol 65: 162–169.
49. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, et al. (1994) A broadly
neutralizing human monoclonal antibody against gp41 of human immunode-
ficiency virus type 1. AIDS Res Hum Retroviruses 10: 1651–1658.
50. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A
potent cross-clade neutralizing human monoclonal antibody against a novel
epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum
Retroviruses 17: 1757–1765.
51. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human
monoclonal antibody 2G12 defines a distinctive neutralization epitope on the
gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100–
1108.
52. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, et al. (1994)
Recognition properties of a panel of human recombinant Fab fragments to the
CD4 binding site of gp120 that show differing abilities to neutralize human
immunodeficiency virus type 1. J Virol 68: 4821–4828.
Clade C Env Changes during Disease Progression
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e66973
